The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

scientific article

The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/MDS.26613
P3181OpenCitations bibliographic resource ID4880934
P932PMC publication ID5021110
P698PubMed publication ID27113479

P50authorKatrina GwinnQ30501410
Paul TuiteQ56636063
Claire HenchcliffeQ58247734
Un Jung KangQ64198619
Jennifer G GoldmanQ64856649
Roy N AlcalayQ67215512
Amy W AmaraQ83458162
Mark FrasierQ90965725
Catherine KopilQ90965726
Penelope HogarthQ95949292
P2093author name stringHoward Andrews
Tao Xie
Margaret Sutherland
Samuel Frank
Alice Rudolph
Cynthia Casaceli
Lona Vincent
P2860cites workActivity enhances dopaminergic long-duration response in Parkinson diseaseQ24630470
Biomarkers and surrogate endpoints: preferred definitions and conceptual frameworkQ28203935
Parkinson disease in twins: an etiologic studyQ28296110
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)Q28602162
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseasesQ28650457
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairmentQ29615678
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionQ30501271
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder serviceQ33183516
What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic studyQ33220006
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's diseaseQ33631292
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseQ33666297
Salivary DJ-1 could be an indicator of Parkinson's disease progressionQ33719372
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic studyQ34043770
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.Q34140404
The Parkinson Progression Marker Initiative (PPMI).Q34217468
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonismQ34405999
Diagnostic criteria for Parkinson diseaseQ34489839
Levodopa and the progression of Parkinson's diseaseQ34553278
The heterogeneity of idiopathic Parkinson's diseaseQ34621293
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrumentQ34692883
Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain StimulationQ34709458
2009 Biospecimen research network symposium: advancing cancer research through biospecimen science.Q34999433
Description of Parkinson's disease as a clinical syndrome.Q35170978
Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson DiseaseQ35609028
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease studyQ35897974
The clinical features of Parkinson's disease in 100 histologically proven cases.Q36774979
A clinicopathologic study of 100 cases of Parkinson's diseaseQ36776426
Role of DAT-SPECT in the diagnostic work up of parkinsonismQ36814559
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease.Q37129697
Genetics and genomics of Parkinson's diseaseQ38233866
Neuroimaging biomarkers for Parkinson disease: facts and fantasyQ38264397
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyQ39783457
Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patientsQ39803136
LRRK2 secretion in exosomes is regulated by 14-3-3.Q42149865
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease.Q42772374
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study GroupQ44801417
The clinically important difference on the unified Parkinson's disease rating scale.Q46001806
Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosisQ48494045
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scaleQ50251495
Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: A population-based studyQ51973259
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing resultsQ57083753
Weight loss in Parkinson's diseaseQ57127663
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onsetQ81147302
Identification of blood microRNAs associated to Parkinsonĭs diseaseQ83372764
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
biomarkerQ864574
P304page(s)924-932
P577publication date2016-04-26
P1433published inMovement DisordersQ1486418
P1476titleThe BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
P478volume31

Reverse relations

cites work (P2860)
Q90569829Bringing radiomics into a multi-omics framework for a comprehensive genotype-phenotype characterization of oncological diseases
Q93075108CSF and blood biomarkers for Parkinson's disease
Q64865985Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms
Q89686598Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease
Q47902561Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Q47657093Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
Q90655862Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis
Q64057961Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease
Q57142239Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Q57971633Finding useful biomarkers for Parkinson's disease
Q99609969Mining genetic and transcriptomic data using machine learning approaches in Parkinson's disease
Q58585963Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?
Q47338262Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program

Search more.